Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Eicosapentaenoic acid and docosapentaenoic acid monoglycerides are more potent than docosahexaenoic acid monoglyceride to resolve inflammation in a rheumatoid arthritis model

Fig. 1

Effects of MAG-ω3 compounds on arthritis severity. a Hind paw thickness (mm) as a function of time (days) was measured in control and in complete Freund’s adjuvant (CFA) rats, either untreated or treated with docosahexaenoic acid monoglyceride (MAG-DHA), eicosapentaenoic acid monoglyceride (MAG-EPA) or docosapentaenoic acid monoglyceride (MAG-DPA) (318 mg/kg). MAG-ω3 compounds were administered at 15 days post-CFA injection onward. Six control and six CFA rats were sacrificed on day 22 at the same time as CFA + MAG-ω3-treated rats for pro-inflammatory marker analyses, whereas six controls and six CFA rats were sacrificed on day 29 to evaluate the progression of arthritis over time. Results represent the mean ± standard error of the mean (n = 6 per group for MAG-ω3-treated animals and n = 12 for control and CFA rats). b Clinical arthritis score as a function of time was determined in untreated and treated CFA rats (n = 12 for untreated and n = 6 for treated conditions). c Macroscopic images of hind paw derived from control, CFA and CFA+MAG-EPA-treated rats. Hematoxylin-eosin staining of hind paw thin sections derived from Control (d): CFA (e) and CFA + MAG-EPA-treated animals (f). Bar = 50 μm

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us